Dupilumab

• Long-term effect of Dupilumab on acetylsalicylic acid (ASA) intolerance and its mechanisms in patients with non-steroidal anti-inflammatory … Pending
  2024-520082-31-01 Phase IV 1 country Medical University Of Vienna
• DIRECTION Study Pending
  2025-524495-39-00 Phase IV 1 country Medical University Of Vienna
• BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL) Pending
  2025-524741-28-00 Phase IV 1 country Amsterdam UMC Stichting
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting
  2025-521268-37-00 Phase IV 10 countries Sanofi-Aventis Recherche & Developpement
• A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and femal… Recruiting
  2024-514737-37-00 Phase III 8 countries Sanofi-Aventis Recherche & Developpement
• A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants with Eosinophilic Gastritis with or without Eosinophilic Duod… Recruiting
  2022-500795-62-00 Phase II 3 countries Regeneron Pharmaceuticals Inc.
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab ( Switch-Up ) Recruiting
  2025-523347-35-00 Phase III/IV 3 countries AbbVie Deutschland GmbH & Co. KG
• WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial Recruiting
  2024-516789-13-00 Phase IV 1 country Centre Hospitalier Universitaire De Toulouse
• The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement Recruiting
  2023-509111-89-00 Phase III 1 country Medical University Of Gdansk
• Tapering of biologics in chronic rhinosinusitis with nasal polyps Recruiting
  2024-519758-35-01 Phase IV 1 country Rigshospitalet
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 Phase III 12 countries AbbVie Deutschland GmbH & Co. KG
• Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: the effect on comorbid eosinophilic otitis media Recruiting
  2023-508068-31-00 Phase IV 1 country Amsterdam UMC
• the BIRDIE trial Recruiting
  2023-505839-12-01 Phase III 1 country Sint Franciscus Vlietland Groep Stichting
• Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment resp… Recruiting
  2023-506165-62-00 Phase IV 1 country Hospital Universitario La Paz
• Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting
  2023-508879-36-00 Phase III 6 countries Sanofi-Aventis Recherche & Developpement
• Complete remission study Ended
  2024-519628-25-00 Phase IV 1 country Rigshospitalet
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation t… Ended
  2023-510458-18-00 Phase IV 3 countries Regeneron Pharmaceuticals Inc.
• A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and fema… Ended
  2024-514762-39-00 Phase III 7 countries Sanofi-Aventis Recherche & Developpement
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended
  2023-504331-41-00 Phase III 9 countries Sanofi-Aventis Research & Development
• DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority ran… Ended
  2023-504171-24-00 Phase IV 1 country Amsterdam UMC
• Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended
  2022-502250-14-00 Phase IV 1 country Rigshospitalet
• Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized tr… Ended
  2022-501179-23-00 Phase IV 1 country Centre Hospitalier Universitaire De Nantes
• Effect of Dupilumab an mucus plugs and inflammatory patterns in sEvere asThmAtiC paTients — a Pilot Study (DETACT) Ended
  2024-517567-23-00 Phase III/IV 1 country Medical University Of Vienna
• Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients with Uncontrolled Moderate to Sev… Ended
  2024-513423-16-00 Phase IV 7 countries Sanofi-Aventis Recherche & Developpement

Showing 1–24 of 30 trials